Navigation Links
Combo Inhaler May Give Better Relief for Some With Asthma
Date:3/4/2013

By Steven Reinberg
HealthDay Reporter

MONDAY, March 4 (HealthDay News) -- Asthma patients typically use two inhaled drugs -- one a fast-acting "rescue inhaler" to stem attacks and another long-lasting one to prevent them.

However, combining both in one inhaler may be best for some patients, two new studies suggest.

Patients with moderate to severe asthma who used a combination inhaler had fewer attacks than those on two separate inhalers, researchers report. Both studies tested the so-called SMART (single maintenance and reliever therapy) protocol.

"The SMART regime was more effective as a treatment for asthma than the conventional treatment, where you just use a inhaler at a fixed maintenance dose and a short-acting inhaler for the relief of symptoms," said Dr. Richard Beasley, director of the Medical Research Institute of New Zealand in Wellington and lead researcher of one of the studies.

These drugs are a combination of a corticosteroid (such as budesonide or fluticasone) and a long-acting beta-2 agonist (such as salmeterol or formoterol) and are sold under various brand names including Seretide, Symbicort and Advair.

In asthma, treatment increases as the severity of the condition does, Beasley said. So, this combination therapy isn't the first choice. When the asthma is difficult to control with other methods, "we are now recommending the SMART regime," he said.

"You treat the patients according to their needs," Beasley said. "This is certainly not what you start them on -- it is something you would use on moderate to severe patients."

In the United States, use of these combination inhalers is also not considered first-line therapy for asthma, according to Dr. Len Horovitz, a pulmonary specialist at Lenox Hill Hospital in New York City.

"Patients, however, are currently using these combination inhalers," he said. If the asthma is moderate to severe, then a combination inhaler is appropriate, said Horovitz, who was not involved with either new study.

The reports were published in the March issue of the journal Lancet Respiratory Medicine.

One study was funded by Italian pharmaceutical company Chiesi Farmaceutici, whose products include asthma medications. The multi-center European study was led by Dr. Klaus Rabe, a professor of pulmonary medicine at the University of Kiel, in Germany.

The study included more than 1,700 patients with moderate asthma. Researchers found that participants using the single, combination inhaler had significantly fewer severe asthma attacks and were seen at a hospital or urgent medical facility less than those patients using the two inhalers.

Rabe and colleagues wrote that although drugs like Symbicort (the specific budesonide/formoterol combination used in the study) can be more expensive than separate inhalers, the ability to prevent asthma attacks and reduce hospital and emergency room visits may be cost-saving in the end.

In the second trial, funded by the Health Research Council of New Zealand, Beasley's team randomly assigned 303 patients to the single-inhaler protocol or to usual care with two inhalers. Over six months, the researchers found that those using Symbicort had fewer severe asthma attacks.

One concern had been that patients using the combination inhaler would get overexposed to corticosteroid or would overuse the inhaler, Beasley said.

They found, however, that patients using the combination inhaler reduced their overuse of corticosteroid by 40 percent, compared to those using separate inhalers.

While those in the SMART program took in more corticosteroids a day, they had fewer asthma attacks so their overall exposure to corticosteroid was the same as for people in the two-inhaler group, the New Zealand researchers explained.

More information

For more about asthma, visit the U.S. National Library of Medicine.

SOURCES: Richard Beasley, M.B., director, Medical Research Institute of New Zealand, Wellington; Len Horovitz, M.D., pulmonary specialist, Lenox Hill Hospital, New York City; March 2013 Lancet Respiratory Medicine


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Experimental Chemo Combo for Colon Cancer Disappoints
2. Value of Metformin, Insulin Combo for Type 2 Diabetes Questioned
3. Two-Drug Combo Helps Teens With Migraines
4. Two-Drug Combo May Be Safe for Melanoma Treatment
5. Breast cancer clinical trial tests combo of heat shock protein inhibitor and hormonal therapy
6. Combo Therapy May Help Ease Ringing in the Ears
7. FDA Approves Combo Shot for Meningitis, Hib in Kids
8. Booze, Energy Drinks, Casual Sex Combo Common in College: Study
9. Drug combo better for common type of metastatic breast cancer, UCI-led study finds
10. Double drug combo could shut down abnormal blood vessel growth that feeds disease
11. Cooking-Oil Combo May Improve Blood Pressure
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Combo Inhaler May Give Better Relief for Some With Asthma
(Date:12/8/2016)... ... December 08, 2016 , ... The Florida Hospital ... and Hyperbaric Medical Society (UHMS), the leading authority in hyperbaric medicine. This accreditation ... a few hospitals and facilities have earned this distinction. This is the second ...
(Date:12/8/2016)... ... 2016 , ... Mirixa Corporation , a leading healthcare ... patient care services, has announced the promotions of Karen Litsinger to senior vice ... sales. , Litsinger joined Mirixa in 2008 after serving as a partner ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... modes of access for customers and employees that are both engaging and easy ... with Service Smart Technology, the software company revealed today its plans to roll ...
(Date:12/8/2016)... ... , ... California Senate Bill (SB) 863, signed into law in 2012, may ... 2014, according to CompScope™ Medical Benchmarks for California, 17th Edition , a study ... medical payments per claim in California decreased 4 percent in 2013 and then 3 ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... planning services from offices headquartered in Hamilton County, is embarking on a charity ... LuvFurMutts specializes in finding new homes for orphaned or neglected senior dogs in ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... -- IRIDEX Corporation (NASDAQ: IRIX ) today announced ... stock, $0.01 par value (the "Offering" with such shares being ... terms of the Offering will depend on market and other ... no assurance as to whether or when the Offering may ... proceeds it will receive from this offering for working capital ...
(Date:12/8/2016)... 8, 2016 Global Interventional Radiology Market: ... global interventional radiology market analyzes the current and ... an elaborate executive summary, including a market snapshot ... sub-segments. The research is a combination of ... bulk of our research efforts along with information ...
(Date:12/8/2016)... -- Eli Lilly and Company (NYSE: LLY ) ... trial at the 9 th Clinical Trials on ... not meet the primary endpoint in the EXPEDITION3 clinical ... mild dementia due to Alzheimer,s disease (AD), and Lilly ... treatment of mild dementia due to AD. ...
Breaking Medicine Technology: